Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
-
- Leverages large genomic database from Scipher’s testing business.- Proven Spectra™ platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships....
-
-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine...
-
WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with WellDyne, a...